



**Washington State Health Care Authority
Prescription Drug Program**

626 8th Ave SE, Olympia, WA 98501 • 206-521-2029

<https://www.hca.wa.gov/about-hca/prescription-drug-program>

September 28, 2020

Dear Interested Party,

Based on recommendations by the Washington State Pharmacy and Therapeutics Committee, the Health Care Authority, Uniform Medical Plan (UMP), and the Department of Labor & Industries (L&I) have named the following drugs as preferred in their respective therapeutic classes on the Washington State Preferred Drug List (PDL), effective October 1, 2020 for UMP, and effective January 1, 2021 for L&I:

Diabetes – Long-acting Insulins reviewed 8/15/2018		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
insulin glargine	Basaglar Kwikpen pen	No	Yes
The effect of this recommendation is no change to the WA PDL.			

Diabetes Drugs – DPP-4 reviewed 2/19/2020		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
alogliptin benzoate	alogliptin tablet	No	Yes
alogliptin/metformin HCL	alogliptin/metformin HCL tablet	No	Yes
alogliptin/pioglitazone	alogliptin/pioglitazone tablet	No	Yes
linaglipton	Tradjenta [®] tablet	No	Yes
linagliptin + metformin	Jentadueto [®] tablet	No	Yes
	Jentadueto XR [®] tablet	No	Yes
The effect of this recommendation is no change to the WA PDL.			

Diabetes Drugs – GLP-1 Agonist		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
exenatide	Byetta [®] solution	No	Yes
	Byetta [®] pen	No	Yes
liraglutide	Victoza [®] solution	No	Yes
semaglutide	Ozempic [®] pen	No	Yes
	Rybelsus [®] tablet	No	Yes
The effect of this recommendation is to make Ozempic [®] and Rybelsus [®] preferred on the WA PDL.			

Diabetes Drugs – SGLT2 Inhibitors		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
dapagliflozin propanediol	Farxiga [®] tablet	No	Yes
dapagliflozin/ metformin ER	Xigduo XR [®] tablet	No	Yes
empagliflozin	Jardiance [®] tablet	No	Yes
empagliflozin/ metformin HCL	Synjardy [®] tablet	No	Yes
	Synjardy XR [®] tablet	No	Yes
The effect of this recommendation is no change to the WA PDL.			

Long Acting Opioids reviewed 12/20/2017		Agency Coverage	
Ingredient Name	Label Name of Preferred Products	L&I	UMP
fentanyl	fentanyl patch	No	Yes
hydromorphone HCL	hydromorphone HCL ER	No	Yes
morphine sulfate	morphine sulfate CR tablet	No	Yes
	morphine sulfate ER capsule	No	Yes
	morphine sulfate ER tablet	No	Yes
oxycodone HCL	oxycodone HCL ER tablet	No	Yes
oxymorphone HCL	oxymorphone ER tablet	No	Yes
The effect of this recommendation is to make oxymorphone ER preferred on the PDL.			

Overactive Bladder – Long Acting reviewed 6/20/2018		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
darifenacin hydrobromide	darifenacin hydrobromide ER tablet	Yes	Yes
oxybutynin chloride	oxybutynin chloride ER tablet	Yes	Yes
solifenacin succinate	solifenacin succinate tablet	Yes	Yes
tolterodine tartrate	tolterodine tartrate ER capsule	Yes	Yes
tropium chloride	tropium chloride ER capsule	Yes	Yes
The effect of this recommendation is make darifenacin hydrobromide ER and solifenacin succinate preferred on the WA PDL.			

Overactive Bladder – Short Acting		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
oxybutynin chloride	oxybutynin chloride syrup	Yes	Yes
	oxybutynin chloride tablet	Yes	Yes
tolterodine tartrate	tolterodine tartrate tablet	Yes	Yes
tropium chloride	tropium chloride tablet	Yes	Yes
The effect of this recommendation is no change to the WA PDL.			

PCSK9 Inhibitors reviewed 10/16/2019		Agency Coverage	
Ingredient Name	Label Name of Preferred Product	L&I	UMP
evolocumab	Repatha® injection	No	Yes
	Repatha Pushtronex System® on-body infusor with prefilled cartridge	No	Yes
	Repatha Sureclick® injection	No	Yes
The effect of this recommendation is no change to the WA PDL.			

Each agency will use the common PDL according to its benefit structure. You may view the current PDL on our [website](#).

If you have other questions or comments regarding this announcement, please contact Leta Evaskus at (206) 521-2029 or by email at leta.evaskus@hca.wa.gov.

Sincerely,



Donna Sullivan
 Chief Pharmacy Officer
 Clinical Quality and Care Transformation
 Washington State Health Care Authority